Robert Frank Cornell

9PUBLICATIONS
39CO-AUTHORS
Haematological tumoursPredictive and prognostic markersGene and molecular therapyMolecular targetsMedical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Feb 02, 2026
Causal Effects of Hydrophilic Bile Acids on Carfilzomib-Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization Study.

Samia Shabnaz, Eric Farber-Eger, Marwa Tantawy

|May 24, 2024
Metabolomic signatures of carfilzomib-related cardiotoxicity in patients with multiple myeloma.

Samia Shabnaz, Trang N Nguyen, Roy Williams

|Dec 13, 2021
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.

Luciano J Costa, Saurabh Chhabra, Eva Medvedova

|Nov 24, 2021
A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma.

Robert Frank Cornell, Rachid Baz, Joshua R Richter

|Sep 25, 2020
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.

Robert Cornell, Parameswaran Hari, Shijie Tang

|Aug 01, 2019
Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma.

Susan Bal, Allison Weaver, Robert F Cornell

Pageof 2

Frequent Collaborators

3 joint publications

Luciano J Costa

3 joint publications

Rachid C Baz

2 joint publications

Samia Shabnaz

2 joint publications

Marwa Tantawy